Tasly Pharmaceutical Group Bilan de santé

Santé financière contrôle des critères 6/6

Tasly Pharmaceutical Group possède un total de capitaux propres de CN¥13.0B et une dette totale de CN¥2.1B, ce qui porte son ratio d'endettement à 16.2%. Son actif total et son passif total sont CN¥16.8B et de CN¥3.8B. L'EBIT de Tasly Pharmaceutical Group est CN¥1.4B ce qui fait que son ratio de couverture des intérêts -44.7. Elle dispose de liquidités et de placements à court terme de CN¥5.0B.

Informations clés

16.2%

Ratio d'endettement

CN¥2.11b

Dette

Ratio de couverture des intérêts	-44.7x
Argent liquide	CN¥4.97b
Fonds propres	CN¥13.02b
Total du passif	CN¥3.82b
Total des actifs	CN¥16.83b

Mises à jour récentes de la santé financière

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Jul 22

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15

Recent updates

Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Nov 17

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Jul 22

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Jun 13

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

May 13

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Apr 26

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 600535 ( CN¥9.1B ) dépassent ses passifs à court terme ( CN¥3.4B ).

Passif à long terme: Les actifs à court terme de 600535 ( CN¥9.1B ) dépassent ses passifs à long terme ( CN¥456.4M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 600535 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 600535 a été réduit de 71% à 16.2% au cours des 5 dernières années.

Couverture de la dette: La dette de 600535 est bien couverte par le flux de trésorerie opérationnel ( 126.6% ).

Couverture des intérêts: 600535 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

Tasly Pharmaceutical Group Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Recent updates

Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Consensus EPS estimates fall by 14%

Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.22 in 3Q 2023)

Upcoming dividend of CN¥0.26 per share

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 23% overvalued

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 24, 2024

Price target increased by 8.7% to CN¥16.17

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Now 20% overvalued

Dividend of CN¥0.33 announced

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 1Q 2023)

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Price target decreased by 7.0% to CN¥13.88

Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024

Now 21% undervalued after recent price drop

Tasly Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 16%

Now 22% undervalued after recent price drop

ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.047 in 3Q 2022)

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

Price target increased by 10% to CN¥12.76

Price target decreased by 13% to CN¥10.64

Consensus EPS estimates fall by 19%

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.10 in 2Q 2022)

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 12%

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued

Price target increased by 9.3% to CN¥12.10

Price target increased by 7.3% to CN¥11.79

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 8.0% to CN¥10.99

Consensus EPS estimates fall by 35%

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.047 (vs CN¥0.32 in 3Q 2021)

Price target decreased to CN¥10.19

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 2Q 2021)

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CN¥14.34

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Price target increased to CN¥16.52

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall to CN¥1.03

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.27 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.26 in 2Q 2020)

Consensus revenue estimates fall to CN¥7.67b

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.20 in 1Q 2020)

Tasly Pharmaceutical Group Co., Ltd to Report Fiscal Year 2020 Results on Mar 30, 2021

Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) dropped from S&P Global BMI Index

New 90-day low: CN¥13.57

New 90-day low: CN¥14.49

Price target raised to CN¥19.43

New 90-day low: CN¥14.83

New 90-day low: CN¥16.61

Earnings beat expectations, revenue disappoints

New 90-day high - CN¥19.62

Earnings released

Chongqing Pharmaceutical (Group) Co., Ltd. completed the acquisition of Tianjin Tasly Medicine Distribution Group CO.,LTD. from a group of shareholders.